#medullary thyroid cancer

[tockamybeloved]

[atassociation12]

https://www.thyroid.org/

The American Thyroid Association® (ATA) is the professional home for clinicians and researchers dedicated to thyroid health. Learn more and join us.

[myhealingera]

Two weeks after this photo was taken, I received a phone call that nobody ever wants to receive.

I was dealing with a slew of health issues: an inability to lose weight, hair loss, swollen lymph nodes, fatigue so intense that getting out of bed felt like a miracle, and severe brain fog. My joints were in so much pain that I found myself using a heating pad for most of the day.

I consulted my aunt, who is a pediatrician, and she reviewed my recent blood work. She observed that my TSH levels were consistently borderline high, often surpassing the normal threshold. Encouraged by her insight, I visited my OBGYN and shared my symptoms. She ordered hormone testing and referred me to a rheumatologist, given that lupus runs in my family. The results indicated elevated TSH, DHEA, and C-reactive protein levels.

I then saw a remarkable rheumatologist who conducted over 120 tests. All came back normal except for my thyroid antibodies, and I was diagnosed with arthritis in my hands. Around this time, my neck began to swell, feeling as though something was stuck in my throat. My primary care physician scheduled an ultrasound, which revealed swelling in my neck and a lymph node, and identified a nodule or "ectopic" tissue.

Returning to my primary care doctor, I was told my lab results were normal and advised to follow up in a year, despite continuing to experience swollen lymph nodes and being told that the neck nodule was unrelated to the swelling. At this point had been to urgent care 3 times, completed 3 rounds of steroids, a z-pack, and tested negative for mono, Covid, and strep.

Despite my tendency to avoid conflict, something felt off, and I knew I wasn't okay.

I requested a referral to an endocrinologist, which I received, but they couldn't see me until after Christmas. Not wanting to wait, I found another endocrinologist who could see me on Halloween. At my first appointment, I was diagnosed with Hashimoto’s thyroiditis and hypothyroidism. She ordered a biopsy "to be safe," emphasizing that a finding warrants investigation. Even at the hospital for my biopsy, the PA questioned its necessity given my primary care's advice to wait a year.

On 12/22, my endocrinologist informed me that the biopsy results were suspicious for thyroid carcinoma. I returned on 1/5 to discuss the findings.

They had sent my sample for Afirma testing, a genetic test for medullary thyroid cancer, due to the unusual results and the aggressive nature of the potential cancer.

I was then referred to an ENT, who suspected the nodule might actually be a lymph node. A CT scan confirmed this suspicion, revealing a lymph node suspicious for thyroid cancer, yet with no nodules on my thyroid itself.

The decision was made to remove the lymph node, with intraoperative pathology consultation to decide whether to also remove the thyroid.

On 2/24, the lymph node was removed, but pathology was indeterminate, leading to the decision not to remove the thyroid.

The following week, I was informed that my results had been sent to a larger university hospital for further analysis and a second opinion, an ominous sign according to my ENT.

Ultimately, it was confirmed as papillary thyroid cancer that had begun to metastasize to the lymph nodes, indicating occult thyroid cancer, typically undetected until it spreads to the lymph nodes. Likely, there are microcarcinomas on my thyroid undetectable by imaging. Thus, another surgery is required.

My complete thyroidectomy is scheduled for 4/24.

Honestly, none of this truly sank in until I received a call from the hospital's oncology department to schedule a radiation consultation for post-surgery RAI treatment.

It’s been an incredibly tough start to the year, to say the least.

[a-scientific-spirituality]

I have cancer. And not much else.

I am 40.

I got sick in my late 20's. I didn't know what was wrong, I went to doctors and nothing. I blamed stress, I had to drop out of graduate school and figure out living. I ended my marriage, and moved to Denver.

I remarried some time later... and my wife started getting very sick. I continued getting sticker. I was finally diagnosed with medullary thyroid cancer at 35. Incurable. So - I prepared for the worst.

5 months later my wife was injured in a post-surgical -care accident and spent 4 years in a wheelchair.

9 months after she regained the ability to walk, I was diagnosed with ocular melanoma. Five days after that she left. Not because I was sick. But she didn't need me anymore. I don't know if it was ever real

All that aside...I'm 40 now, living at my father's farm in rural Iowa. I'm stranded. I spent Christmas and new years in detox or here as I could not find a doctor in Iowa who would prescribe my bupenorphine while I used Iowa medical Marijuana. I hate it here so much. Over half of my take home income goes immediately out the door to my ex wife.

So... here I am. 2 months now out here. It's COLD on a level Denver wasn't. It's lonely and I miss my partner and my cats and my life in Denver.

I've been pondering the contents of this blog for 30 years. I think I have it sorted now. I've not got much else to do.

Mostly this is something to keep me busy. And i guess it gives me hope. If it gives you hope then I am grateful for that chance.

[snowandstarlight]

okay i mostly use this tag to complain but i figured i’d contribute something semi-educational for once

i’m sure I’m not the first one to think of this (the first one is straight from First Aid), but here’s how i remember the different Multiple Endocrine Neoplasias

MEN I - Ps

     Parathyroid hyperplasia

     Pituitary adenomas

     Pancreatic neuroendocrine tumors

MEN IIa - Cs

     Medullary thyroid cancer (from parafollicular C cells, secretes Calcitonin)

     Parathyroid hyperplasia (elevated Calcium)

     Pheochromocytoma (produces Catecholamines)

MEN IIb - Ms

      Medullary thyroid cancer

     Pheochromocytoma (diagnosed with elevated plasma Metanephrines)

     Marfanoid habitus

     Mucosal neuromas

[impomed]

Selpercatinib 40 & 80 mg in India is a cutting-edge anticancer medication used for treating RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer, including medullary thyroid carcinoma. Available through Impomed Healthcare, this targeted therapy blocks the RET kinase enzyme, slowing cancer cell growth. With its targeted action, flexibility in dosage, and fewer side effects, Selpercatinib 40 & 80 mg in India offers hope and improved survival for cancer patients across the country.

For more information click on this link-:https://www.impomedhealthcare.com

[choithramhospital]

What Are the Early Thyroid Cancer Symptoms of Stage 1, and How Can CMH Freetown Help?

Thyroid cancer is becoming a growing concern worldwide, with cases steadily rising. According to recent studies by the American Cancer Society, thyroid cancer diagnoses have more than tripled over the past three decades. Yet, this is particularly concerning because early symptoms are often subtle and easily overlooked. Recognizing stage 1 thyroid cancer symptoms early is critical, as early detection can lead to more effective treatments and better outcomes.

If you're in Freetown and have been searching for "cancer treatment near me," then CMH Freetown may offer the support you need. In this blog, we will explore the early signs of thyroid cancer, how it develops, and why General Surgery in Freetown might be your best option for effective cancer treatment.

What Is Thyroid Cancer?

Thyroid cancer starts in the thyroid gland, a butterfly-shaped organ located at the base of your neck. It plays a crucial role in regulating your metabolism, heart rate, and body temperature. While thyroid cancer is often slow-growing and may be treatable, recognizing it early is key to preventing the disease from spreading.

Types of Thyroid Cancer

There are four main types of thyroid cancer:

Papillary thyroid cancer: The most common type, making up around 80% of all cases.

Follicular thyroid cancer: Accounts for about 10% to 15%.

Medullary thyroid cancer: Less common, around 4%.

Anaplastic thyroid cancer: A rare, aggressive type, representing less than 2%.

Early Symptoms of Stage 1 Thyroid Cancer

Understanding stage 1 thyroid cancer symptoms is crucial because this is the stage where the cancer is confined to the thyroid and has not yet spread to lymph nodes or other parts of the body. The following symptoms may signal the onset of thyroid cancer, but many can also be mistaken for less serious health issues.

Read More ...

[arrangoiz]

Predicting Survival Outcomes: The Updated AJCC/TNM Staging System

In October 2016: The AJCC (www.cancerstaging.org) published the eighth edition of the AJCC / TNM cancer staging system: Which replaced the seventh edition that had been used by clinicians, cancer registries, and researchers since 2009 On January 1st, 2018: Tumor registries officially began using the eighth edition for tumor staging Whereas the staging tables for medullary thyroid cancer and…

[drcare4u]

FDA Approves Retevmo for Some With Medullary Thyroid Cancer

The FDA has approved Retevmo for select pediatric and adult patients with medullary thyroid cancer who have RET mutations. The Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy. According to the alert from the FDA,…

[tockamybeloved]

Another year as a Meddie survivor! Medullary Thyroid Cancer | ThyCa: Thyroid Cancer Survivors' Association, Inc.

[retevmocapsule]

Retsevmo and Retevmo Available in India

Retsevmo/Retevmo (selpercatinib) is a prescription medication used to treat certain cancers, including lung and thyroid. It targets RET gene mutations, offering a powerful treatment option for patients with these specific cancer types. If you want to buy Retsevmo online in India, please contact Indian Pharma Network (IPN). Specializing in sourcing hard-to-access medications such as Retsevmo, IPN is dedicated to ensuring that patients worldwide, including in India, receive critical, life-saving treatments promptly and efficiently. With IPN’s reliable global network, you can easily order oral Retsevmo from India and have it delivered directly to your location. For more information on how to buy Retsevmo capsules online.

Retsevmo (Selpercatinib) is a targeted therapy used to treat certain types of cancers, such as non-small cell lung cancer (NSCLC) and thyroid cancer. For patients/doctors/hospitals looking to buy Retsevmo in India, it can be challenging due to limited availability in the country. Indian Pharma Network (IPN) specializes in sourcing hard-to-access medicines like Retsevmo. We help facilitate the supply of this life-saving drug across India and globally, ensuring patients receive it promptly. With our international offices in Bulgaria, Belgium, and Hong Kong, we can move medicinal products promptly to every corner of the world. If you need assistance to buy Retsevmo in India.

Retsevmo (Selpercatinib) is a prescription medicine widely used to treat certain types of cancers, such as non-small cell lung cancer (NSCLC) and thyroid cancer, in patients with specific RET gene mutations or fusions. Legal access to Retsevmo in India can be challenging due to limited availability. Indian Pharma Network (IPN) specializes in helping patients, doctors, and hospitals source hard-to-access medicines like Retsevmo. IPN ensures the global delivery of this medicine to every corner of the world, including India. Whether you're a patient or healthcare provider, IPN facilitates the supply of Retsevmo under Named Patient Programs (NPP), ensuring timely access to critical medications. For more information or to place an order.

Retsevmo (Selpercatinib 40 mg) is an FDA-approved oral medication used to treat specific types of lung, thyroid, and other cancers that are caused by abnormal RET genes. It targets and blocks cancer cell growth, providing a personalized approach to cancer treatment. If you’re looking to buy Retsevmo 40 mg capsules, Indian Pharma Network (IPN) can assist in facilitating the supply. Whether you're a patient, doctor, or hospital, we help source hard-to-access medicines like Retsevmo globally. IPN ensures quick and reliable delivery to every corner of the world, offering peace of mind during critical moments.

Retsevmo (selpercatinib 80 mg) is a therapeutic drug used for the treatment of lung and thyroid cancers with a genetic mutation in the RET gene. It is the first therapeutic option available for individuals with an abnormal RET gene. Buy Retsevmo 80 mg capsules at the lowest from India. Indian Pharma Network (IPN) is offering Retevmo Selpercatinib 80 Mg Capsules in New Delhi, Noida, Lucknow, Pune, Bengaluru, Chennai and other major cities in India. Check the best price of Retsevmo (Selpercatinib 80 mg). This oral medication is often hard to access, but with IPN’s network, patients, doctors, and hospitals can order it from trusted international sources.

Retsevmo or Retevmo (Selpercatinib) is a prescription medication used to treat certain types of cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other tumors caused by RET gene alterations. If you are looking for Retsevmo in New Delhi, the Indian Pharma Network (IPN) is here to help. We specialize in sourcing hard-to-access medications like Retsevmo and ensuring they reach patients, doctors, and hospitals in every corner of the world.

[oncologistseemasingh]

Learn about the different types of thyroid cancer, including papillary, follicular, medullary, and anaplastic. Explore this comprehensive guide to gain insights into the diverse nature of thyroid cancer.

[twinkl22004]

“Medullary Thyroid Carcinoma”, Victor McKusick, Mendelian Inheritance in Man, 1966.

Here I present: “Medullary Thyroid Carcinoma”, Victor McKusick, Mendelian Inheritance in Man’, 1966. INTRODUCTION. Medullary thyroid carcinoma (MTC) is a form of thyroid carcinoma which originates from the parafollicular cells (C cells), which produce the hormone calcitonin.   MTC was first characterized in 1959; and, is the third most common of all thyroid cancers. There is evidence familial…

[theindianpharma]

Cabozantinib, a tyrosine kinase inhibitor (TKI) is used for treating several types of cancer, including renal cell carcinoma (RCC), medullary thyroid cancer (MTC), and hepatocellular carcinoma (HCC).

[medchemexpressinhibitor-blog]

Unlocking the Potential of Pralsetinib: Key Facts You Should Know

In the realm of targeted cancer therapies, Pralsetinib has emerged as a groundbreaking option for patients with certain types of tumors. This innovative treatment has generated significant interest due to its specific action against genetic mutations that drive cancer growth. In this article, we will explore essential facts about Pralsetinib, including its mechanism of action, indications, safety profile, and impact on patient care.

1. What is Pralsetinib?

Pralsetinib is an oral tyrosine kinase inhibitor designed specifically to target rearranged during transfection (RET) alterations in various cancers. It has been approved for the treatment of adult patients with advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). By focusing on these specific mutations, Pralsetinib offers a precision medicine approach to cancer treatment.

2. Mechanism of Action

The efficacy of Pralsetinib lies in its ability to selectively inhibit the RET protein, which plays a significant role in cellular signaling pathways involved in tumor growth and survival. By blocking this pathway, Pralsetinib effectively disrupts the signals that promote cancer cell proliferation, leading to reduced tumor growth and improved patient outcomes. This targeted approach minimizes damage to healthy cells, which is a notable advantage over conventional chemotherapy.

3. Indications for Use

Pralsetinib is primarily indicated for:

Non-Small Cell Lung Cancer (NSCLC): Specifically for patients with RET fusion-positive NSCLC who have not received prior systemic therapy.

Medullary Thyroid Cancer (MTC): For patients with advanced MTC who require systemic therapy.

By addressing these specific malignancies, Pralsetinib provides a vital treatment option for patients with limited alternatives.

4. Safety Profile

Understanding the safety profile of Pralsetinib is crucial for healthcare providers and patients alike. In clinical studies, Pralsetinib has been generally well-tolerated, with common side effects including:

Fatigue

Nausea

Diarrhea

Hypertension

While most side effects are manageable, it is essential for patients to communicate openly with their healthcare team to monitor any adverse reactions and adjust treatment as necessary.

5. Administration and Dosage

Pralsetinib is administered orally, usually taken once daily. The specific dosage may vary based on individual patient factors and should be determined by a healthcare provider. This convenient oral formulation allows for flexible dosing schedules, enhancing patient adherence to treatment regimens.

6. The Future of Cancer Treatment

As research continues, the future of Pralsetinib looks promising. Ongoing clinical trials are exploring its effectiveness in additional cancer types with RET alterations and assessing combination therapies to enhance its therapeutic impact. As our understanding of targeted therapies evolves, Pralsetinib may play a pivotal role in shaping the future of personalized cancer care.

Conclusion

Pralsetinib represents a significant advancement in the treatment of RET-altered cancers, offering a targeted approach that improves patient outcomes while minimizing side effects. Its specific indications for non-small cell lung cancer and medullary thyroid cancer underscore its importance in oncology.

For patients eligible for Pralsetinib, discussing this treatment option with a healthcare provider can provide valuable insights into its benefits and potential role in their cancer management plan. As we continue to uncover the potential of targeted therapies, Pralsetinib stands out as a beacon of hope for many individuals battling cancer. Stay informed about ongoing developments and consider the possibilities that Pralsetinib brings to modern cancer treatment.

Please visit MedChemExpress https://www.medchemexpress.co